RE:RE:RE:RE:RE:RE:RE:RE:GENEREX INKS $50 MILLION LICENSING DEAL WITH CHINA PARTNERS If Vaxils Vaxhit platform fails to find a viable vaccine, then l would assume "full validation" of the platform will not be forthcoming..... the whole Vaxil pipeline will be in jeopardy and l would assume the company's reputation would also be in jeopardy.....that is the risk they are taking by basing the candidate on the platform...lf they don't share the Army's data then we can assume failure and the company's future will be in question for sure
bigbanktheory wrote: bligicka wrote: In my opinion yes they need a advantage over those competitors and others that may even raise the bar further......has their been any failures as of yet ???
bigbanktheory wrote: Padina wrote: No its not a waste of time. The liitle funds from PP is needed to take them to a ceratin milestone which will make them an ideal candidate for a partnership or qualify them for a grant.
Partners want something with little or no risk , A positive Army result wil greatly de-risk VXL and it will also give leverage to vxl on the negotiating table.
The big companies coming out with 90-95% positive results???? And don't quote me on that. Pretty high standard. But not perfect. So does VXL have to be perfect????? Glta, all just a guess and do your dd
Is it possible that even if a company fails, their science could be a small part of the solution???